Collins, M. Some new psychoactive substances: Precursor chemical and synthesis-driver end-products. Drug Test. Anal., 1 Jul 2001, 3 (7–8), 404–416. 178 kB. https://doi.org/10.1002/dta.315
Kavanagh, PV; Power, JD. New psychoactive substances legislation in Ireland – Perspectives from academia. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 884-891. 1.2 MB. https://doi.org/10.1002/dta.1598
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #9
Adamowicz, P; Zuba, D. Discrimination among designer drug isomers by chromatographic and spectrometric methods. In Chromatographic Techniques in the Forensic Analysis of Designer Drugs; Kowalska, T; Sajewicz, M; Sherma, J, Eds., CRC Press, Taylor & Francis Group, 1 Jan 2018; pp 211–232. 1.1 MB.
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report). Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #0. HU-210
EMCDDA. New drugs in Europe, 2009, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2010. 321 kB. #11
Ujváry, I. The bumpy road ahead for forensic scientists. Synthetic cannabinoids to (unwel)come. Spice II Plus, 5 Jun 2014. 405 kB. #HU-210
Wilkinson, SM; Banister, SD; Kassiou, M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Aust. J. Chem., 10 Feb 2015, 68 (1), 4–8. 451 kB. https://doi.org/10.1071/CH14198 #3
Banister, SD; Kumar, KK; Kumar, V; Kobilka, BK; Malhotra, SV. Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain. Med. Chem. Commun., 22 May 2019, 10 (5), 647–659. 810 kB. https://doi.org/10.1039/C8MD00595H #8
Banister, SD; Arnold, JC; Connor, M; Glass, M; McGregor, IS. Dark classics in chemical neuroscience: Δ9-Tetrahydrocannabinol. ACS Chem. Neurosci., 15 May 2019, 10 (5), 2160–2175. 1.8 MB. https://doi.org/10.1021/acschemneuro.8b00651 #26
Al-Zoubi; Morales; Reggio. Structural Insights into CB1 Receptor Biased Signaling. Int. J. Mol. Sci., 13 Apr 2019, 20 (8), 1837. 3.4 MB. https://doi.org/10.3390/ijms20081837 #HU210
Piggee, C. Investigating a not-so-natural high. Anal. Chem., 1 May 2009, 81 (9), 3205-3207. 150 kB. https://doi.org/10.1021/ac900564u #HU-210
Uchiyama, N; Kikura-Hanajiri, R; Shoda, T; Fukuhara, K; Goda, Y. Isomeric analysis of synthetic cannabinoids detected as designer drugs. Yakugaku Zasshi, 1 Jan 2011, 131 (7), 1141–1147. 763 kB. https://doi.org/10.1248/yakushi.131.1141 #HU-210 LC,MS,UV,other
Rhee, M; Vogel, Z; Barg, J; Bayewitch, M; Levy, R; Hanuš, L; Breuer, A; Mechoulam, R. Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of Adenylylcyclase. J. Med. Chem., 1 Sep 1997, 40 (20), 3228–3233. 273 kB. https://doi.org/10.1021/jm970126f #5a NMR,IR